Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation Journal Article
| Authors: | Gomez-Arteaga, A.; Margolskee, E.; Wei, M. T.; van Besien, K.; Inghirami, G.; Horwitz, S. |
| Article Title: | Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 60 |
| Issue: | 7 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2019-01-01 |
| Start Page: | 1626 |
| End Page: | 1631 |
| Language: | English |
| DOI: | 10.1080/10428194.2019.1594220 |
| PUBMED: | 30997845 |
| PROVIDER: | scopus |
| PMCID: | PMC8162842 |
| DOI/URL: | |
| Notes: | Source: Scopus |
